☰

Lei Xu - Publications

Affiliations: 
University of Rochester University of Rochester, Rochester, NY 
Website:
http://www.urmc.rochester.edu/biomedical-genetics/faculty/xu-lab.cfm
Tree Info Grants Similar researchers PubMed Report error

34 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Sagers JE, Beauchamp RL, Zhang Y, Vasilijic S, Wu L, DeSouza P, Seist R, Zhou W, Xu L, Ramesh V, Stankovic KM. Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma. Scientific Reports. 10: 4211. PMID 32144278 DOI: 10.1038/S41598-020-60156-6  0.325
2019 Zhu J, Ke K, Xu L, Jin J. Theoretical studies on the selectivity mechanisms of PI3Kδ inhibition with marketed idelalisib and its derivatives by 3D-QSAR, molecular docking, and molecular dynamics simulation. Journal of Molecular Modeling. 25: 242. PMID 31338599 DOI: 10.1007/S00894-019-4129-X  0.308
2019 Li K, Zhu J, Xu L, Jin J. Rational Design of Novel Phosphoinositide 3-kinase Gamma (PI3Kγ) Selective Inhibitors: A Computational Investigation Integrating 3D-QSAR, Molecular Docking and Molecular Dynamics Simulation. Chemistry & Biodiversity. PMID 31111650 DOI: 10.1002/Cbdv.201900105  0.301
2019 Shen C, Liu H, Wang X, Lei T, Wang E, Xu L, Yu H, Li D, Yao X. Importance of Incorporating Protein Flexibility in Molecule Modeling: A Theoretical Study on Type I NIK Inhibitors. Frontiers in Pharmacology. 10: 345. PMID 31024312 DOI: 10.3389/Fphar.2019.00345  0.308
2019 Zhao Y, Cao J, Melamed A, Worley M, Gockley A, Jones D, Nia HT, Zhang Y, Stylianopoulos T, Kumar AS, Mpekris F, Datta M, Sun Y, Wu L, Gao X, ... ... Xu L, et al. Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma. Proceedings of the National Academy of Sciences of the United States of America. PMID 30659155 DOI: 10.1073/Pnas.1818357116  0.324
2019 Chen J, Landegger LD, Sun Y, Ren J, Maimon N, Wu L, Ng MR, Chen JW, Zhang N, Zhao Y, Gao X, Fujita T, Roberge S, Huang P, Jain RK, ... ... Xu L, et al. A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma. Nature Protocols. PMID 30617350 DOI: 10.1038/S41596-018-0105-7  0.305
2018 Zhu J, Li K, Xu L, Jin J. Insight into the Selective Mechanism of PI3Kγ with Benzothiazole and Thiazolopiperidine γ-specific Inhibitors by in Silico Approaches. Chemical Biology & Drug Design. PMID 30582283 DOI: 10.1111/Cbdd.13469  0.303
2018 Kong X, Sun H, Pan P, Zhu F, Chang S, Xu L, Li Y, Hou T. Importance of protein flexibility in molecular recognition: a case study on Type-I1/2 inhibitors of ALK. Physical Chemistry Chemical Physics : Pccp. PMID 29383359 DOI: 10.1039/C7Cp08241J  0.307
2016 Kloepper J, Riedemann L, Amoozgar Z, Seano G, Susek K, Yu V, Dalvie N, Amelung RL, Datta M, Song JW, Askoxylakis V, Taylor JW, Lu-Emerson C, Batista A, Kirkpatrick ND, ... ... Xu L, et al. Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proceedings of the National Academy of Sciences of the United States of America. PMID 27044098 DOI: 10.1073/Pnas.1525360113  0.404
2016 Peterson TE, Kirkpatrick ND, Huang Y, Farrar CT, Marijt KA, Kloepper J, Datta M, Amoozgar Z, Seano G, Jung K, Kamoun WS, Vardam T, Snuderl M, Goveia J, Chatterjee S, ... ... Xu L, et al. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proceedings of the National Academy of Sciences of the United States of America. PMID 27044097 DOI: 10.1073/Pnas.1525349113  0.352
2016 Yan S, Chatterjee S, Vardam T, Kitahara S, Hato T, Roberge S, Askoxylakis V, Duquette M, Fukumura D, Xu L, Jain R. Abstract A12: Microenvironmental Interleukin-6 induced activation of STAT3 signaling in medulloblastoma: Implications for molecular pathology and therapy Cancer Research. 76. DOI: 10.1158/1538-7445.Pedca15-A12  0.302
2016 Kloepper J, Riedemann L, Amoozgar Z, Seano G, Susek KH, Yu V, Dalvie N, Amelung RL, Datta M, Song JW, Askoxylakis V, Taylor JW, Lu-Emerson C, Batista A, Kirkpatrick ND, ... Xu L, et al. Abstract LB-347: Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-347  0.326
2016 Amoozgar Z, Peterson TE, Kirkpatrick ND, Huang Y, Farrar CT, Marijt KA, Kloepper J, Datta M, Seano G, Jung K, Kamoun WS, Vardam T, Snuderl M, Goveia J, Chatterjee S, ... Xu L, et al. Abstract LB-346: Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-346  0.326
2016 Peterson T, Kirkpatrick N, Huang Y, Farrar C, Marjit K, Kloepper J, Datta M, Amoozgar Z, Seano G, Jung K, Kamoun W, Vardam T, Snuderl M, Goveia J, Chatterjee S, ... ... Xu L, et al. Tmic-07. Dual Inhibition Of Ang-2 And Vegf Receptors Normalizes Tumor Vasculature And Prolongs Survival In Glioblastoma By Altering Macrophages Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.847  0.3
2014 Snurdel M, Batista A, Kirkpatrick N, Almodovar C, Riedemann L, Peterson T, Ferrara N, Klagsbrun M, Duda DG, Fukumura D, Xu L, Carmeliet P, Jain R. Abstract IA17: Targeting placental growth factor/ neuropilin-1 pathway inhibits growth and spread of medulloblastoma Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-Ia17  0.352
2013 Snuderl M, Batista A, Kirkpatrick ND, Ruiz de Almodovar C, Riedemann L, Walsh EC, Anolik R, Huang Y, Martin JD, Kamoun W, Knevels E, Schmidt T, Farrar CT, Vakoc BJ, Mohan N, ... Xu L, et al. Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell. 152: 1065-76. PMID 23452854 DOI: 10.1016/J.Cell.2013.01.036  0.333
2013 Riedemann L, Snuderl M, Batista A, Kirkpatrick ND, Ruiz de Almodovar C, Hasselblatt M, Rossig C, Duda GD, Xu L, Fukumura D, Carmeliet P, Jain RK. Neuropilin-1 (Nrp-1) as a prognostic biomarker and potential drug target for pediatric medulloblastoma. Journal of Clinical Oncology. 31: 2056-2056. DOI: 10.1200/Jco.2013.31.15_Suppl.2056  0.301
2013 Yang L, Mohanty S, Corson N, Xu L. Abstract 210: GPR56 regulates the turnover of tissue transglutaminase and tumor growth in melanoma. Cancer Research. 73: 210-210. DOI: 10.1158/1538-7445.Am2013-210  0.334
2011 Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK. Normalization of the vasculature for treatment of cancer and other diseases. Physiological Reviews. 91: 1071-121. PMID 21742796 DOI: 10.1152/Physrev.00038.2010  0.333
2011 Yang L, Chen G, Mohanty S, Scott G, Fazal F, Rahman A, Begum S, Hynes RO, Xu L. GPR56 Regulates VEGF production and angiogenesis during melanoma progression. Cancer Research. 71: 5558-68. PMID 21724588 DOI: 10.1158/0008-5472.Can-10-4543  0.526
2011 Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D, Jain RK. CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2074-80. PMID 21349998 DOI: 10.1158/1078-0432.Ccr-10-2636  0.324
2010 Xu L, Begum S, Barry M, Crowley D, Yang L, Bronson RT, Hynes RO. GPR56 plays varying roles in endogenous cancer progression. Clinical & Experimental Metastasis. 27: 241-9. PMID 20333450 DOI: 10.1007/S10585-010-9322-3  0.524
2010 Snuderl M, Kirkpatrick ND, Walsh EC, Chung E, Kamoun WS, Peterson TE, Munn LL, Duda DG, Fukumura D, Carmeliet P, Xu L, Jain RK. Abstract LB-363: Inhibition of placental growth factor (PlGF) leads to regression of medulloblastoma Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-363  0.339
2008 Li S, Jin Z, Koirala S, Bu L, Xu L, Hynes RO, Walsh CA, Corfas G, Piao X. GPR56 regulates pial basement membrane integrity and cortical lamination. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 28: 5817-26. PMID 18509043 DOI: 10.1523/Jneurosci.0853-08.2008  0.442
2008 Xu L, Shen SS, Hoshida Y, Subramanian A, Ross K, Brunet JP, Wagner SN, Ramaswamy S, Mesirov JP, Hynes RO. Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Molecular Cancer Research : McR. 6: 760-9. PMID 18505921 DOI: 10.1158/1541-7786.Mcr-07-0344  0.474
2007 Xu L, Jain RK. Down-regulation of placenta growth factor by promoter hypermethylation in human lung and colon carcinoma. Molecular Cancer Research : McR. 5: 873-80. PMID 17704140 DOI: 10.1158/1541-7786.Mcr-06-0141  0.302
2007 Xu L, Hynes RO. GPR56 and TG2: possible roles in suppression of tumor growth by the microenvironment. Cell Cycle (Georgetown, Tex.). 6: 160-5. PMID 17314516 DOI: 10.4161/Cc.6.2.3760  0.558
2007 Lawenda BD, Smith DE, Xu L, Niemierko A, Silverstein JR, Boucher Y, Kashiwagi S, Held KD, Jain RK, Loeffler JS, Eisenberg DM, Blumberg JB. Do the dietary supplements epigallocatechin gallate or vitamin e cause a radiomodifying response on tumors in vivo? A pilot study with murine breast carcinoma. Journal of the Society For Integrative Oncology. 5: 11-7. PMID 17309809 DOI: 10.2310/7200.2006.033  0.308
2007 Xu L, Begum S, Hearn JD, Hynes RO. GPR56 binds tissue transglutaminase and inhibits melanoma tumor growth and metastasis The Faseb Journal. 21. DOI: 10.1096/Fasebj.21.5.A267-D  0.525
2006 Xu L, Begum S, Hearn JD, Hynes RO. GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis. Proceedings of the National Academy of Sciences of the United States of America. 103: 9023-8. PMID 16757564 DOI: 10.1073/Pnas.0602681103  0.563
2006 Xu L, Cochran DM, Tong RT, Winkler F, Kashiwagi S, Jain RK, Fukumura D. Placenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse models. Cancer Research. 66: 3971-7. PMID 16618713 DOI: 10.1158/0008-5472.Can-04-3085  0.319
2001 Tsuzuki Y, Carreira CM, Bockhorn M, Xu L, Jain RK, Fukumura D. Pancreas microenvironment promotes VEGF expression and tumor growth: Novel window models for pancreatic tumor angiogenesis and microcirculation Laboratory Investigation. 81: 1439-1451. PMID 11598156 DOI: 10.1038/Labinvest.3780357  0.33
2001 Brown EB, Campbell RB, Tsuzuki Y, Xu L, Carmeliet P, Fukumura D, Jain RK. In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nature Medicine. 7: 864-8. PMID 11433354 DOI: 10.1038/89997  0.309
2000 Xu L, Yoneda J, Herrera C, Wood J, Killion JJ, Fidler IJ. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. International Journal of Oncology. 16: 445-54. PMID 10675474 DOI: 10.3892/Ijo.16.3.445  0.33
Show low-probability matches.